Representative Steve Scalise revealed on Tuesday that he has been diagnosed with Multiple Myeloma, a form of blood cancer. "After a few days of not feeling like myself this past week, I had some blood ...

Not a day goes by in clinic without a patient asking about the recent New York Times article on multiple myeloma: "Doc, is there really a cure now? I want this treatment." The article was boldly ...

Histopathological image of multiple myoloma. Smear preparation of bone marrow aspirate stained with May-Grünwald-Giemsa procedure. It doest not represent a histopathologic image but essentially helps ...

PRINCETON, N.J., September 23, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ...

Antibodies that bind to two targets are an established way of treating the blood cancer multiple myeloma. Aiming to top those medicines, AbbVie has secured rights to an early-clinical drug that works ...

Researchers at Dana-Farber Cancer Institute have developed a blood test that could transform the diagnosis and monitoring of multiple myeloma (MM) and its precursor conditions. The new method, known ...

Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with standard-care ...

The Department of Veterans Affairs has started the process to designate multiple myeloma and acute and chronic leukemias as linked to military service in the Persian Gulf, Afghanistan and elsewhere, a ...

As many as one third of newly diagnosed multiple myeloma (MM) cases are classified as high risk, with widely varying rates of progression-free survival (PFS), as shown in a validation of consensus ...

Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last ...

Researchers at Duke University have shown that blocking an enzyme involved in iron regulation not only kills multiple myeloma cancer cells, but also increases the effectiveness of current therapies ...